Progenics cuts workforce, focuses on oncology after Relistor rejection
This article was originally published in Scrip
Executive Summary
On the back of US FDA rejection of the supplemental new drug application (sNDA) for Relistor (methylnaltrexone bromide), Tarrytown, New York-based Progenics Pharmaceuticals has laid off 26% of its employees, bringing the company's headcount to 77, to focus its resources on a previously announced shift favouring oncology programmes.